KRT16 and psoriasis: Representative histological effects of efalizumab (Figure 3E) and K16 staining (Figure 3F) demonstrate normalization of psoriatic inflammation, and K16 expression by week 12, and the histological features of relapse, which are clinically consistent with psoriasis.